A Phase 1/2 interventional study of Angiotensin-(1-7) and Placebo in Covid19, sponsored by Stanford University. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-03.
Sponsored by Stanford University · Phase 1/2, Interventional, and Treatment
The primary objective is to evaluate the safety and efficacy of intravenous (IV) infusion of Ang (1-7) compared to placebo with respect to time to recovery, disease severity, need for mechanical ventilation or extracorporeal membrane oxygenation (ECMO), and mortality in patients with COVID 19.
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
Browse COVID-19 studies →Stanford University is the lead sponsor of 2,117 studies on the registry; 425 are open to participants now.
Of its 259 completed or terminated interventional studies of FDA-regulated products, 197 (76%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants receive treatment for 7 days.
Drug: Angiotensin-(1-7)
Participants receive treatment for 7 days.
Drug: Placebo
Ang (1-7) administered by continuous intravenous (IV) infusion
Placebo (normal saline) administered by continuous intravenous (IV) infusion
Time to recovery
Time to recovery, defined as attaining a score of 6, 7, or 8 on the COVID-19 disease severity scale, an 8 point ordinal scale used in the NIH Adaptive COVID-19 Treatment Trial (ACTT; NCT04280705). 1. = Death; 2. = Hospitalized and on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. = Hospitalized and on non-invasive ventilation or high-flow oxygen devices; 4. = Hospitalized and requiring supplemental oxygen; 5. = Hospitalized and not requiring supplemental oxygen but requiring ongoing medical care (COVID-19-related or otherwise); 6. = Hospitalized and not requiring supplemental oxygen and no longer requiring ongoing medical care; 7. = Not hospitalized, limitation on activities and/or requiring home oxygen; 8. = Not hospitalized, no limitation on activities
Time frame: Up to 29 days
Incidence of mortality at Day 29
Time frame: 29 days
Number of days alive and not on mechanical ventilator or ECMO in the 28 days following first dose
Time frame: Up to 29 days
Number of participants requiring mechanical ventilation or ECMO, or dying, through Day 29
Time frame: Up to 29 days
COVID-19 disease severity scale score on Day 8
COVID-19 disease severity scale (range; 1-8, higher scores correspond to better health state).
Time frame: Day 8
COVID-19 disease severity scale score on Day 15
COVID-19 disease severity scale (range; 1-8, higher scores correspond to better health state).
Time frame: Day 15
COVID-19 disease severity scale score on Day 22
COVID-19 disease severity scale (range; 1-8, higher scores correspond to better health state).
Time frame: Day 22
COVID-19 disease severity scale score on Day 29
COVID-19 disease severity scale (range; 1-8, higher scores correspond to better health state).
Time frame: Day 29
Plan to share: No
No publications or documents are linked to this record.
This study is withdrawn, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stanford University